cyrilzakka/clinical-trials huggingface dataset:
Google Health Search Trial

There are large differences in knowledge between patients and healthcare providers (i.e. physicians, physician assistants and nurse practitioners), and there is a strong interest on the part of both industry and academia to reduce the gap in knowledge between patients and healthcare providers. Currently, about 1 in 20 searches on Google are health related. Among internet users, 72% reported searching for health information, and among persons who use mobile phones, 31% of cell phone users and 52% of smartphone users have looked up health or medical information. Oftentimes, patients will search on Google or other search engines in order to find health conditions that explain their symptoms prior to visiting their healthcare provider. With the launch of Google's new health search tools for mobile devices (i.e. smartphones, tablets, etc.) it is important to understand how patients use these search platforms and what their effects are on clinical encounters. The main objective of this study is to understand the accuracy of differential diagnoses generated by Google searching; the investigators hypothesize that searching on Google using a tablet or mobile device will be more accurate than not using any search tool, and that the new health search experience will improve accuracy over the standard search platform.


Eligibility Criteria:
Inclusion Criteria:

* Adult patient \>= 18 years of age
* Presenting for care at urgent care or emergency department
* In search of a diagnosis to explain a new symptom or group of symptoms

Exclusion Criteria:

* Not literate, defined as lacking the ability to read and write (self-reported)
* Non-English Speaking (self-reported)
* Not mentally competent to provide consent due to inability to understand relevant information due to deficit in intelligence (e.g. mental retardation), memory (e.g., advanced dementia or significant delirium), or attention span (e.g., Attention Deficit Disorder (ADD) or mania) based on prior documentation in medical records or as judged by the researchers)
* Unable to use phone/tablet for any mental or physical impairment (e.g., blind) (self-reported)
* Exacerbation of chronic condition (self-reported)
Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome

Idiopathic membranous nephropathy (IMN) is one of the most common forms of nephrotic syndrome (NS) in adults and is usually treated by corticosteroids in combination with cytotoxic drugs especially cyclophosphamide or cyclosporine. Tacrolimus, a new immunosuppressive agent, was proved to be effective in treating refractory NS. Whether it is effective in IMN has not been reported. We therefore undertook a multi-center, controlled study to investigate the efficacy and safety profile of tacrolimus compared with cyclophosphamide in the treatment of patients with idiopathic membranous nephropathy and nephrotic syndrome.

Idiopathic membranous nephropathy (IMN) is one of the most common forms of nephrotic syndrome (NS) in adults and is usually treated by corticosteroids in combination with cytotoxic drugs especially cyclophosphamide or cyclosporine. However, the effect was not satisfying and the side-effects of the above immunosuppressive agents were often a worrying problem. Tacrolimus, a new immunosuppressive agent, was proved to be effective in treating refractory NS especially FSGS. Whether it is effective in IMN has not been reported. We therefore undertook a multi-center, controlled study to investigate the efficacy and safety profile of tacrolimus compared with cyclophosphamide in the treatment of patients with idiopathic membranous nephropathy and nephrotic syndrome.

Eligibility Criteria:
Inclusion Criteria:

* All patients were diagnosed as idiopathic membranous nephropathy according to renal histology, with nephrotic syndrome, serum creatinine less than 2.5mg/dL, 18\~70 years old, signed the informed consent and willing to be followed up according to the protocol.

Exclusion Criteria:

* Patients who had received immunosuppressive therapy within the previous 3 months, complicated other severe renal diseases, serum creatinine higher than 2.5mg/dL, severe infection, diabetes mellitus, liver disease, pregnancy, lactating, and anticipated poor compliance with the protocol.
Long-term Assessment of the Safety and Performance of the NuVasive Simplify Disc

A prospective, multicenter post-market clinical follow-up study to evaluate the 10-year long-term safety and effectiveness of the Simplify Disc in subjects who were enrolled in the post approval study (NCT04630626).


Eligibility Criteria:
Inclusion Criteria:

1. Subject was enrolled in the Simplify Disc post approval study (NCT04630626) at a participating study site
2. Subject understands the conditions of enrollment and is willing to sign an informed consent form to participate in the study

Exclusion Criteria:

1. Subject had an SSI at the index level during the post approval study (NCT04630626)
2. Subject was withdrawn or withdrew consent to participate in the post approval study (NCT04630626)
A Comparison of Two Different Surgical Techniques for Total Hip Resurfacing

This study compares the posterior approach to the anterolateral approach using the ReCap® Total Hip Resurfacing System.

Theoretical considerations of RECAP procedures through anterolateral trochanteric osteotomy:

* Less bone resection, less complicated revision surgery.
* Reduced stress shielding of the femur.
* Lower incidence of hip dislocations.
* Walking function improved by change in mobilisation regime and operative technique.
* Risk of femoral neck fracture is reduced by preoperative measurement of bone density.
* Risk of avascular necrosis of the femoral head is reduced with the anterolateral approach preserving femoral head blood supply and preventing later failure of the implant.

Eligibility Criteria:
Inclusion Criteria:

* Primary hip OA
* Secondary hip OA due to mild and moderate acetabular dysplasia
* Sufficient bone quality for cementless acetabular component
* Suited for resurfacing of the femoral head (pre- and intraoperatively assessed)
* \>29 years
* \<61 years

Exclusion Criteria:

* Neuromuscular or vascular diseases in affected leg
* Patients found intra-operatively to be unsuited for a cementless acetabular component or cementing of the femoral component
* Need of NSAID post-operatively
* Fracture sequelae
* Females at risk of pregnancy (no safe contraceptives)
* Severe hip dysplasia
* Sequelae from hip disease in childhood
* Medicine with large effect on bone density (K-vitamin antagonists, loop-diuretic)
* Alcoholism (females \> 14 units per week, males \> 21 units per week) AVN
* Osteoporosis
Management of Sleep Apnea Patients by a Clinical Nurse (Supernurse)

Sleep apnea is a prevalent problem and references for the evaluation of this condition often exceeds the sleep clinic's capacity thus creating important delays in the patients' care.

The overall goal of this project is to assess the feasibility and the non-inferiority of integrating a clinical nurse, or supernurse, to the initial consultation team.

The hypothesis is that the integration of a clinical nurse to the sleep clinic's evaluation team is non inferior in terms of patients' outcomes such as improvement of symptoms and quality of life as well as adherence to treatment.

This study is supported by funding dedicated to teaching and research activities related to sleep-disordered breathing.


Eligibility Criteria:
Inclusion Criteria:

* Patients referred to the ''Institut Universitaire de Cardiologie et Pneumologie de Québec'' 's sleep clinic who have undergone a cardiorespiratory polygraphy.
* Body mass index (BMI) between 27-35 kg/m2;
* Apnea-Hypopnea Index (ADI) equal or above 20 events per hour with less than 5 events per hour of central origin;
* Oxygen Desaturaton Index (ODI) equal or above 10 events per hour;
* Percentage of time spent below 90% of oxygen saturation equal or less than 10%

Exclusion criteria :

- Patients not meeting the above inclusion criteria.
Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers

The purpose of this study is to evaluate safety and reactogenicity of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) manufactured by GPO, in Thailand to previously healthy Thais.

It is a phase I randomized placebo controlled trial (vaccine and placebo ratio of 2:1). A phase II study is planned to be conducted following review of results of this phase.

Phase I: It is a double blind randomized placebo controlled trial involving 24 participants age 18-49 years (16 will receive vaccines and 8 will receive placebo). All will be admitted in the isolation ward for 10-14 days after each immunization mainly for safety assessment. Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) will be given by intranasal route 21 days apart. Each group of 4 participants will be immunized at a time at 30-60 mins interval. All participants will be followed 21 days after each immunization. Total follow up is 60 day.

Eligibility Criteria:
Inclusion Criteria:

* Healthy
* Age 18-49 years old
* Having Thai ID card or equivalent
* Are seronegative to the specific H5 influenza virus determined by antibody titer less than 1:40 by HAI test to the corresponding antigen.
* Anti HIV - Negative
* All hematology \& biochemistry and urine analysis are within normal range or of no clinical significance (not more than 1.5 times of normal value)
* Able to read and write and sign written informed consent.

Exclusion Criteria:

* Known history of egg allergy
* Having had recently influenza infection confirmed as H5
* History of bronchial asthma
* History of chronic lung diseases
* History of chronic rhinitis
* History of immunodeficiency state
* History of immunosuppression
* History of heavy smoking (more than 5 rolls per day)
* History of alcoholic (pure drink 200 ml per day)
* Acute infectious and noninfectious diseases (within 2 weeks)
* Exacerbation of chronic diseases or cancer or HIV positives
* Anamnestic leukocytosis, hepatitis B and C positives
* The volunteers who have been taking immunoglobulin products or have had a blood transfusion during past three months before the beginning of the experiment
* Participation in other research study or stop participant less than 1 month
* Pregnancy or plan to become pregnant for 60 days after enrollment or breast feeding
* Any concomitant medication with Aspirin
* The volunteers who have family members with immunodeficiency
* Poultry workers
* Have undertaken international travel within the one week prior to immunization
Companion Dog & Loneliness in Elderly Persons

Elderly may have problems to create personal connections or to have physical activities in their day- to - day life; loneliness and social isolation may increase fragility in this population. Companion dog presence favours social relations, affective feelings and physical exercises. On the other hand dog presence raises risk of falling and has a cost for its owner. This project seeks to assess positive impacts of companion dog presence in elderly living at home. This transdisciplinar study (general practionners, veterinarians, dog instructors, nurses, researchers) evaluates loneliness and social isolation between elderly with or without a companion dog at home.

Objective:To Evaluate the link between companion dog presence and loneliness in elderly persons living at home Method: An Observational, multicentric, transversal, national, comparative study (elderly with companion dog vs elderly without a dog). 200 subjects needed


Eligibility Criteria:
Inclusion Criteria:

* person aged ≥ 75years old
* living at home

Exclusion Criteria:

* bedridden person
* person accompanied by any animal, other than a dog
* EPHAD based (establishments providing care for the dependent elderly)
* comprehension or reading difficulties in french affecting study participation and scales assessment
* cognitive, mental ou psychic disorders
* person under legal protection
Investigating the Safety and Performance of Two New 1-piece Ostomy Products Compared With SenSura 1-piece

The aim of the current investigation is to investigate the performance of two new 1-piece ostomy products

The present investigation aims at testing the performance and safety of the two new 1-piece ostomy products

Eligibility Criteria:
Inclusion Criteria:

1. Have given written informed consent and signed letter of authority (mandatory in DK)
2. Be at least 18 years of age and have full legal capacity.
3. Be able to handle the products themselves
4. Have an ileostomy with a diameter between 10 and 40 mm.
5. Have had their ostomy for at least three months.
6. Have within the last month used a 1-piece flat product with open bag
7. Currently using midi or maxi bags
8. Willing to use minimum 1 product every second day, i.e. maximum 2 days wear time.
9. Be suitable for participation in the investigation
10. Must be able to use custom cut product
11. Negative result of a pregnancy test for women of childbearing age (only DK)

Exclusion Criteria:

1. Currently receiving or have within the past 2 months received radio- and/or chemotherapy.
2. Currently receiving or have within the past month received systemic steroid or local treatment in the peristomal area
3. Are pregnant or breastfeeding
4. Participating in other interventional clinical investigations or have previously participated in this investigation
5. Has participated in the previous explorative Coloplast studies CP236 and CP237
6. Are currently or during the study using ostomy belt
7. Has a stoma below skin surface
8. Currently suffering from peristomal skin problems (i.e.bleeding and/or broken skin)
9. Has known hypersensitivity towards any of the test products
Ketogenic Diet for Recurrent Glioblastoma

To determine whether a mild ketogenic diet can influences quality of life and survival of patients with recurrent glioblastoma

Increased glycolysis and reduced oxidative phosphorylation is a characteristic property of many tumors. A change of nutrition by limiting carbohydrates and increasing the proportion of fatty acids and proteins can lead to ketogenic metabolism and might limit energy production in tumor cells and therefore inhibit tumor growth. Standard treatment for glioblastoma includes resection, irradiation and temozolomide chemotherapy. If there is tumor recurrence, no standard therapy is established. Therapeutic options in this situation include resection, irradiation or another chemotherapy. However, some patients cannot be treated in this situation, because none of the available treatment options seems reasonable or applicable, for example if no additional chemotherapy can be started at the time of recurrence due to myelosuppression. The pilot study examines whether in this situation a ketogenic diet can be applied to the patients and may inhibit tumor growth and influence the quality of life of the patients.

Eligibility Criteria:
Inclusion Criteria:

* age \>= 18 years
* histological diagnosis of glioblastoma or gliosarcoma
* on MRI measurable tumor
* interval of at least 6 months after primary resection
* completed radiotherapy, interval of at least 3 months after completion of radiotherapy
* relapse during or after temozolomide chemotherapy, other chemotherapy not possible, not reasonable or not wanted by the patient
* Karnofsky-Index \>= 60%, ECOG \<= 2
* life expectancy of at least 12 weeks
* creatinine \<= 1.5 mg/dl, urea \<= 50 mg/dl
* INR \<= 1,5, GOT \<= 7 x of normal value, GPT \<= 7 x of normal value

Exclusion Criteria:

* bowel obstruction or subileus
* diabetes mellitus, HbA1c \> 6,1 %
* heart failure (NYHA \> 2), myocardial infarction within the last 6 months, atrial fibrillation
* acute infection
* conditions that may strongly reduce compliance to the diet or increase risk of the diet
* dementia or clinically relevant alterations of the mental state which interfere with the applicability of the diet
An Investigation of the Gait Performance and Balance in Yoga Instructors

Yoga is a popular exercise and thought to be beneficial to many aspects such as mood, flexibility and balance, etc. Gait performance is a indicator of overall health and functional status. This study aims to investigate whether or not yoga instructors have a more symmetric gait pattern and better balance ability than healthy people without experience of performing Yoga. Inertial measurement units (IMUs) will be used to gather data related to gait symmetry and single leg stance balance. A comparison by four performance indexes related to gait symmetry and balance will be made to quantify the potential advantages of yoga practice.

Yoga is a form of exercise with a focus on the structural alignment of the physical body. As Yoga movements involve a complex motion of core muscles and lower limb muscles, this exercise may be beneficial for gait stability. Gait performance is a sensitive indicator of overall health and functional status, and gait impairment can lead to a high risk of falling or diminished mobility. It was hypothesized that yoga instructors may have a more symmetric gait pattern and better balance ability than healthy non-yoga controls. Impact of yoga training on gait symmetry and single leg stance balance will be investigated. Twenty five yoga instructors and twenty five age/sex-matched healthy subjects will be recruited to conduct walking and static stability tests and these subjects' gait data and body movements will be measured during the experiments by attaching inertial measurement units (IMUs) to their lower limbs and trunks. Calculation of the subjects' asymmetry of swing phases during their gait cycles will be done to evaluate the gait performance. Afterwards, subjects will conduct four different one-leg stance tests. Two balance indexes will be defined and the recorded IMU data will be applied to evaluate the subjects' balance ability. Four performance indexes will then be defined to assess gait performance and single leg stance stability to quantify the potential advantages of yoga practice.

Eligibility Criteria:
\[Yoga instructor\]

Inclusion Criteria:

* overall good health and can cooperate with orders reasonably
* between the ages of 25 to 60 years old
* practicing three to six days per week and at least ten years of experience in yoga

Exclusion criteria

* limb or leg discrepancy
* history of surgery on the lower limbs or spine
* history of musculoskeletal injury over the lower back in the past six months

\[Healthy control\]

Inclusion Criteria:

* overall good health and can cooperate with orders reasonably
* between the ages of 25 to 60 years old
* participated in regular exercise 2 or 3 times a week

Exclusion criteria

* limb or leg discrepancy
* history of surgery on the lower limbs or spine
* history of musculoskeletal injury over the lower back in the past six months
* experience of Yoga practicing
Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)

Smoking is a significant cause of damage to health and quality of life specifically for Veterans with human immunodeficiency virus (HIV). Smoking cessation interventions for this population are lacking. The primary aim of this project is to explore smoking cessation treatment preferences among Veteran smokers living with HIV. The study team will refine the design and content of a smoking cessation treatment for Veteran smokers living with HIV. The intervention uses mobile health and telehealth technology to personalize smoking cessation counseling and medications and provide relapse prevention text messaging.

Although smoking is a significant cause of damage to health and quality of life specifically for Veterans with human immunodeficiency virus (HIV), smoking cessation interventions for this population are lacking. The primary aim of this project is to qualitatively explore smoking cessation treatment preferences among Veteran smokers living with HIV. The study team will refine the design and content of an intervention that uses mobile health and telehealth technology to a)individually personalize smoking cessation counseling and pharmacotherapy, and b) provide relapse prevention messaging support. It is a personalized, tailored, multi-component intervention for smoking cessation specifically designed for Veteran smokers living with HIV.

This project is highly significant given that: 1) smoking is prevalent among and particularly harmful for HIV-positive Veterans; 2) there is a dearth of research on smoking cessation for Veterans with HIV; 3) current approaches to smoking cessation in this population are not effective; 4) as the largest US provider of HIV health services, VHA is an ideal setting; and 5) the proposed intervention follows the VA Blueprint for Excellence, which prioritizes mobile health and treatment personalization to increase reach/efficacy.

Eligibility Criteria:
Inclusion Criteria:

* VHA patient
* HIV positive serostatus
* currently smoking 7 cigarettes per week
* willing to complete study procedures. Exclusion criteria are:

Exclusion Criteria:

* current hospitalization
* acute risk for suicide documented in the medical record
* inability to complete study procedures.
Active Drug Surveillance Program of Ferriprox Use

Observational, open label, prospective, multi-center, post-marketing drug surveillance program.

A post-marketing, drug surveillance program evaluating the use, monitoring, benefits and adverse effects of Ferriprox under clinical conditions in newly treated patients.

Eligibility Criteria:
Main Inclusion Criteria:

* Patients who started Ferriprox therapy less than one month or are to initiate Ferriprox therapy at the time of enrolment into the program.

Main Exclusion Criteria:

* Patients treated with Ferriprox for more than one month prior to enrolment.